Soligenix stock dips on pricing $5.0 million securities offering
Seeking Alpha News (Thu, 18-Apr 8:47 AM ET)
Soligenix stock dips on pricing $4.75 million securities offering
Seeking Alpha News (Thu, 18-Apr 8:47 AM ET)
Soligenix Announces Pricing of $4.75 Million Public Offering
PRNewswire (Thu, 18-Apr 8:30 AM ET)
BSGM, ENLV and WISA among mid-day movers
Seeking Alpha News (Mon, 15-Apr 12:47 PM ET)
Soligenix stock soars 106% on FDA orphan drug status
Seeking Alpha News (Mon, 15-Apr 10:13 AM ET)
PRNewswire (Mon, 15-Apr 7:30 AM ET)
PRNewswire (Thu, 11-Apr 7:30 AM ET)
PRNewswire (Wed, 3-Apr 7:30 AM ET)
Soligenix Announces Recent Accomplishments and Year End 2023 Financial Results
PRNewswire (Fri, 15-Mar 7:30 AM ET)
Soligenix Announces Formation of Behet's Disease Medical Advisory Board
PRNewswire (Thu, 8-Feb 7:30 AM ET)
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
Soligenix trades on the NASDAQ stock market under the symbol SNGX.
As of April 19, 2024, SNGX stock price declined to $0.43 with 929,660 million shares trading.
SNGX has a beta of 0.39, meaning it tends to be less sensitive to market movements. SNGX has a correlation of 0.00 to the broad based SPY ETF.
SNGX has a market cap of $4.54 million. This is considered a Sub-Micro Cap stock.
Last quarter Soligenix reported $205,453 in Revenue and -$.06 earnings per share. This beat revenue expectation by $5,453 and exceeded earnings estimates by $.13.
In the last 3 years, SNGX stock traded as high as $24.00 and as low as $.37.
The top ETF exchange traded funds that SNGX belongs to (by Net Assets): VXF.
SNGX has underperformed the market in the last year with a price return of -74.9% while the SPY ETF gained +21.2%. SNGX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -24.9% and -8.6%, respectively, while the SPY returned +3.0% and -4.5%, respectively.
SNGX support price is $.39 and resistance is $.48 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SNGX stock will trade within this expected range on the day.